DDInter631 DDInter1376
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Eltrombopag {u} (Compound) binds {v} (Gene) CYP2C8
Eltrombopag {u} (Compound) is included by {v} (Pharmacologic Class) Thrombopoietin Receptor Agonists
Eltrombopag {u} may cause a minor interaction that can limit clinical effects when taken with {v} Boceprevir
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Eltrombopag {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Eltrombopag {u} may lead to a major life threatening interaction when taken with {v} Peginterferon alfa-2b
Eltrombopag (Compound) binds CYP2C8 (Gene)
Eltrombopag (Compound) is included by Thrombopoietin Receptor Agonists (Pharmacologic Class)
Eltrombopag may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Eltrombopag may lead to a major life threatening interaction when taken with Berotralstat
Eltrombopag may lead to a major life threatening interaction when taken with Peginterferon alfa-2b